Table 2.
Baseline demographic and clinical characteristics of the propensity-weighted full Work Productivity and Activity Impairment questionnaire-respondent pseudo-population
| Baseline demographic and clinical characteristics | Ocrelizumab (n = 445) | Oral DMTs (n = 394) | p value | Ocrelizumab (n = 356) | Injectable DMTs (n = 282) | p value |
|---|---|---|---|---|---|---|
| Age, years (mean ± SD) | 41 ± 25 | 41 ± 12 | 0.87 | 42 ± 23 | 43 ± 13 | 0.35 |
| Female sex, n (%) | 267 (60) | 244 (62) | 0.86 | 206 (58) | 176 (62) | 0.73 |
| Education, n (%) | 0.52 | 0.86 | ||||
| Greater than high school | 375 (84) | 312 (79) | 296 (83) | 230 (81) | ||
| High school or less | 70 (16) | 82 (21) | 60 (17) | 52 (19) | ||
| Line of therapy, n (%) | 0.77 | 0.87 | ||||
| ≥ 2 | 218 (49) | 205 (52) | 139 (39) | 105 (37) | ||
| 0–1 | 227 (51) | 189 (48) | 217 (61) | 177 (63) | ||
| Disease subtype, n (%) | 0.89 | 0.78 | ||||
| RRMS | 420 (94) | 374 (95) | 334 (94) | 262 (93) | ||
| SPMS | 25 (6) | 20 (5) | 22 (6) | 20 (7) | ||
| EDSS score at treatment initiation, n (%) | 0.79 | 0.84 | ||||
| ≥ 3 | 83 (19) | 79 (20) | 73 (20) | 54 (19) | ||
| 0–2 | 362 (81) | 315 (80) | 283 (80) | 228 (81) | ||
| Years since diagnosis (mean ± SD) | 4.4 ± 11 | 5.1 ± 5.8 | 0.25 | 4.3 ± 12 | 6.4 ± 6.8 | < 0.01 |
| Years on current therapy, n (%) | 0.96 | 0.39 | ||||
| ≥ 1 | 365 (82) | 322 (82) | 292 (82) | 246 (87) | ||
| < 1 | 80 (18) | 72 (18) | 64 (18) | 26 (13) |
EDSS Expanded Disability Status Scale, RRMS relapsing–remitting multiple sclerosis, SPMS secondary progressive multiple sclerosis